Bit Digital
BTBT
Riot Platforms
RIOT
Cipher Mining
CIFR
CleanSpark
CLSK
Bitdeer Technologies
BTDR
US Stock MarketDetailed Quotes
DTIL Precision BioSciences
- 4.7500
- +0.0600+1.28%
Close Jan 3 16:00 ET
36.44MMarket Cap-16.96P/E (TTM)
4.8997High4.6050Low154.58KVolume4.8600Open4.6900Pre Close737.92KTurnover2.48%Turnover RatioLossP/E (Static)7.67MShares19.429952wk High0.56P/B29.59MFloat Cap3.610052wk Low--Dividend TTM6.23MShs Float710.1060Historical High--Div YieldTTM6.28%Amplitude3.6100Historical Low4.7730Avg Price1Lot Size
Trending US Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks
Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.
Precision BioSciences Stock Forum
📊⚡️📊
Precision BioSciences Receives Approval in Hong Kong to Expand Pbgene-Hbv Phase 1 Eliminate-B Trial for the Treatment of Chronic Hepatitis B
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data and Phase 1 Clinical Trial Plans on November 15, 2024
Precision BioSciences (Nasdaq: DTIL) announced a virtual Hepatitis B Investor Event scheduled for November 15, 2024. The event will feature Key Opinion Leaders and members of Precision's Hepatitis Scientific Advisory Board discussing the current hepatitis B treatment landscape, which only achieves 1-3% func...
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Efficiency Gene Editing Utilizing Homology-Directed Repair at the ESGCT 31st Annual Congress
Precision BioSciences (Nasdaq: DTIL) presented preclinical data at the ESGCT 31st Annual Congress showcasing their ARCUS platform'scapability for high-efficiency gene editing through homology-directed repair (HDR). The research demonstrated gene insertion rates exceeding 85% ...
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B
Precision BioSciences (NASDAQ: DTIL) has received its first Clinical Trial Application (CTA) approval in Moldova for PBGENE-HBV, marking the first in vivo gene editing program for chronic hepatitis B virus to enter global clinical trials. The program aims to cure chronic hepatitis B by eliminating ccc...
Precision BioSciences Inc: Payment Includes $9.75 Mln Cash and $3.25 Mln in Imugene Limited Ordinary Shares Precision BioSciences Receives $13 Million in Proceeds From Imugene Convertible Note Maturity as Part of the August 2023 Azer-Cel Deal
Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis
No comment yet